Frequency of significant steatosis in various chronic liver diseases: an evaluation with Transient Elastography (TE)

• Main Authors: Shahrani, Shahreedhan, balakrishnan, Preetica mayuri, ravi, Koshni, singh, sandeep, chee, sher wye, zulkeflie, saiful hasyim, ng, ying zhuang, lee, wai kin, AK, Mohamed amin, Sooi, Choong Yeong, CK, vikneshwaran, Nik Muhamad Affendi, Nik Arsyad, skantha, ruben, Limun, Mohd Fairul, Wan ibrahim, Nik Razima, Mohamed Talha, Abdul Malik, Chuah, Kee Huat, Stanley, khoo, Rajaram, Ruveena Bhavani, chan, wah keong, Mahadeva, Sanjiv,
• Format: Conference or Workshop Item
• Language: English; English
• Published: 2022
• Subjects: R Medicine (General)
• Online Access: http://irep.iium.edu.my/99671/1/GUT%202022%20SP%20-%2017%20%28Digital%20Copy%29.pdf; http://irep.iium.edu.my/99671/2/99669_FREQUENCY%20OF%20SIGNIFICANT%20FIBROSIS.pdf; http://irep.iium.edu.my/99671/
• Institution: Universiti Islam Antarabangsa Malaysia

INTRODUCTION: TE was developed as a non-invasive method to assess liver fibrosis and steatosis using shear wave velocity. Many studies have proven its’ effectiveness as a method for evaluating liver fibrosis and steatosis.1-2 OBJECTIVE: To determine the prevalence and aetiology of steatosis in our local population. METHOD: This study was conducted as a retrospective review on all patients who had TE performed at UMMC from 1 January 2013 to 31 December 2021. Their demographics, clinical characteristics and TE findings were charted. RESULTS: A total of 3066 patients were included. 51.7% were males and 48.3% were females. The median CAP value was 271 dB/m. The median E value was 6.5kPa. 61.2% of patients had steatosis, with a staggering number of of these patients having significant steatosis (51.8%). 6.3% of patients had S2 steatosis whereas 45.5% of patients had severe (S3) steatosis. Interestingly, in those with S2 steatosis, 34.7% had chronic hepatitis B (CHB), 31.5% had non-alcoholic fatty liver disease (NAFLD), 5.2% with chronic hepatitis C (CHC) and 1% had alcoholic liver disease (ALD). In the S3 steatosis group, 66.7% had NAFLD, followed by ALD (36.6%), CHB (30.1%) and CHC (27.7%). 221 DISCUSSION: It is important to highlight that a large proportion of our patients has significant steatosis. This is likely in keeping with the global rise of obesity and sedentary lifestyle.3 NAFLD is a 4-decades old nomenclature that does not appropriately address the heterogenous pathogenicity of fatty liver disease. Our study reflects this heterogeneity, as it shows that steatosis often co-exists with other diverse aetiologies. CONCLUSION: Whilst NAFLD clearly has the greatest frequency of severe steatosis, it is also present in other aetiologies. These findings support the new terminology of metabolic associated fatty liver disease (MAFLD), which reflects the fact that NAFLD commonly co-exists with other aetiologies.